Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
AssigneesAllogene Therapeutics, Inc., Les Laboratoires Servier
InventorsCyril Alkis KONTO, Amina ZINAI
Life of this patent
Estimating the term…
Abstract
The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.
Claims20
A method of treating a subject who has non-Hodgkin's lymphoma comprising administering to the subject allogeneic chimeric antigen receptor (CAR)-T cells (CAR-T cells) comprising an anti-human CD19 4-1BB/CD3zeta CAR, wherein the method comprises administering to the subject at least one unit dose of 120×106 cells/dose to 360×106 cells/dose, and wherein the anti-human CD19 4-1BB/CD3zeta CAR comprises an amino acid sequence of SEQ ID NO:1.
Dependencies are inferred from the claim text.